• Samsung Bioepis: Applying The "Hunger" For Biosimilars To Novel Drugs
    Samsung Bioepis: Applying The "Hunger" For Biosimilars To Novel Drugs

    Since last year's feature article celebrating Samsung Bioepis' fifth anniversary, the company has seen a number of approvals and launches and has established a novel biologics development partnership. As such, I jumped on the opportunity to learn more about the company's ongoing efforts to realize a lower COGS, speed production, and manage risk in biosimilar and biologics development.

New U.S And Canadian Facilities Boosting Biologics Capacity

Biopharma executives have warned they need more biologics development and manufacturing capacities, particularly in North America. They haven’t been howling at the moon. Four announcements – within two days of each other – offer a sign of relief. And Amgen has provided Outsourced Pharma with its first public estimate of costs for one of those facilities.

Why Biosimilars Won’t Be “A Stake In The Heart Of Innovation”

There has not been much discussion about how biosimilars contribute to or will impact innovation — outside of helping the healthcare system afford costly novel therapies. I found my interest in this question sparked upon reading a recent headline, "Biosimilars: The Cure for Sky-High Drug Prices Or A Stake In The Heart Of Innovation?"

2018 Outlook: Biosimilar Trends To Watch

Last week, I published the first installment of a three-part roundtable discussion highlighting which 2017 trends/occurrences were most notable to the members of Biosimilar Development’s editorial advisory board. In addition to discussing 2017’s impact on the future of the industry, these experts also shared their thoughts on what to expect in 2018.

Top 5 Biosimilar Developments Of 2017

These top five events reflect the steps the numerous industry stakeholders are taking to build what they hope will be a biosimilar friendly framework in the U.S. Though a number of these developments could bring positive implications for the biosimilar industry moving forward, several of these have raised a number of questions and concerns.

More From Our Editors


  • Targeted Therapy In Bacterial Infections: Taking A Page From Oncology’s Playbook
    Targeted Therapy In Bacterial Infections: Taking A Page From Oncology’s Playbook

    This article will focus on approaches used to manage infections caused by common pathogens, the current landscape of targeted antibacterial therapy, and the challenges and areas of opportunity for both developers of antibacterial therapies and manufacturers of medical devices.

  • Bridging The Public Knowledge Gap Around Cell And Gene Medicine
    Bridging The Public Knowledge Gap Around Cell And Gene Medicine

    Cell and gene therapies hold the potential to transform medicine; however, if patients are to gain access to these therapies, we must increase public awareness and understanding of how these therapies can benefit them. According to a review of recent research studies that measured U.S. public opinion related to gene medicine,1 the public is not yet aware of gene medicine; is unfamiliar with the terms being used to describe the topic; and, when faced with multiple therapeutic options, is worried about making informed decisions.

  • EMA’s Revised Format For Risk Management Plans – What You Need To Know
    EMA’s Revised Format For Risk Management Plans – What You Need To Know

    The revised format for the EU Risk Management Plan sets a new milestone in a progressive approach to risk management. The new RMP template is a straightforward and well-structured document that can be used by RMP experts, and the concepts behind risk management have been justified to better reflect the stages of the life span of a medicinal product.

  • Should You Rotate Disinfectants? Industry Experts Weigh In

    Whether to rotate disinfectants has been debated in the pharmaceutical industry for years. If disinfectants are not used properly, microorganisms may remain on surfaces and proliferate in the environment. This article discusses the concept of disinfectant rotation and the current mainstream industry practice regarding it.

  • Will Biosimilars Trigger The Next Wave Of Blockbuster Biologics?

    Gone are the days when we could count the number of immunology drugs on the market with our two hands. Today, the market is crowded with not only an abundance of originator biologics, but also an increasing supply of biosimilar products

More From Guest Contributors


  • 5 Reasons External Collaborations Fail In Drug Discovery

    This white paper, brought to you by Dassault Systèmes BIOVIA, discusses the different types of external collaborations research organizations engage in, the reasons that many of these partnerships fail to meet expectations, and an informatics solutions to overcome these issues.

  • The Future Of BioManufacturing

    The biomanufacturing industry is undergoing a major shift, from single-product processes and stainless steel infrastructure to flexible, multi-product facilities using single-use technology.

More Bioprocessing White Papers


  • RABS vs. Isolator – Technology and Applications
    RABS vs. Isolator – Technology and Applications

    Considerable confusion still surrounds the terms barrier, Restricted Access Barrier System, and isolator and their respective suitability and favorability in pharmaceutical fill-finish operations. 

  • Introduction to Chromatography for Protein Purification
    Introduction to Chromatography for Protein Purification

    Whether these proteins are produced by recombinant DNA technology or extracted from sources such as plasma, they need to be highly purified — and the purification process must satisfy a variety of regulations.

  • The Key To Unlocking Foreign Pharmaceutical Markets
    The Key To Unlocking Foreign Pharmaceutical Markets

    The opportunities in developing global markets appear limitless, but the obstacles surrounding them can be daunting. With issues ranging from language barriers to protecting intellectual property rights, each solution must be as unique as the country the work is developed in. Download this eBook to learn key strategies to unlock foreign pharma markets.

  • The Future Is “Cloudy” For Data Integrity In Life Sciences
    The Future Is “Cloudy” For Data Integrity In Life Sciences

    Managing the integrity of manufacturing data is becoming ever more challenging, particularly as more and more critical manufacturing functions are outsourced, thus limiting the amount of oversight a pharmaceutical company can provide. Life science companies need to demonstrate control over their data—whether internally or externally generated. FDA officials indicate that “data that are not valid and trustworthy is a sign that an entire operation or facility is out of control and cannot assure the quality of its medicines”. Without accurate data, companies are less equipped to ensure the safety, effectiveness and quality of their products.

  • Solving The OOS Problem With Continuous Manufacturing
    Solving The OOS Problem With Continuous Manufacturing

    With continuous manufacturing, it is possible to monitor product quality continuously, and make adjustments in real time to keep the product in spec.

More Industry Insights


3rd Annual Lay Summaries Summit September 24 - 25, 2018
Philadelphia, PA
16th Annual Cold Chain Global Forum September 24 - 28, 2018
Philadelphia, PA
PAP Legal Update September 25 - 26, 2018
Arlinton, VA
Finance & Accounting for Bioscience Companies September 25 - 26, 2018
Boston, MA
4th Annual Bio/Pharmaceutical Product Launch Summit September 25 - 26, 2018
Cambridge, MA
More Industry Events


The Top Method Validation Mistakes – And How to Avoid Them October 8 - 8, 2018
1pm-2:30pm EST, Online Training
How FDA and MHRA Decide Which Drug Facilities to Inspect – and at What Frequency October 16 - 16, 2018
1pm-2:30pm EDT, Online Training
Stability Programs - Key Factors in Meeting FDA/ICH Expectations October 25 - 25, 2018
1pm-2:30pm EST, Online Training
More Upcoming Courses